In conclusion, our study underscores the pivotal role of IGF2BP3 in driving cisplatin resistance in bladder cancer, primarily by stabilizing CDK6 mRNA in an m6A-dependent manner. Here, IGF2BP3 is linked to urinary bladder cancer.